Uterine Cancer Diagnostic Testing Market: Pegged for Robust Expansion During 2017 – 2025

Uterine cancer, commonly, is a form of cancer in female reproductive system which usually initiates in the tissues of uterus. The most common type of gynecologic cancer occurring worldwide is cervical cancer that arises from the lower portion of uterus, while the second most common cancer is endometrial cancer which initiates in endometrium, the lining of uterus. Endometrial cancer is the most common type of uterine cancer, commonly found in women going through menopause.

Women with an average age of 60 years are the most likely to diagnose with endometrial cancer. As per the American Cancer Society, it has been anticipated that in 2017, about 61,380 new cases of uterus body cancer would be diagnosed in United States and around 10,920 women will die of uterine body cancer. Uterine body cancers include both uterine sarcomas and endometrial cancers. According to World Health Organization, developed regions such as North America followed by Europe registers greater incidence rate for endometrial uterine cancer owing to the changing lifestyle opted by women.

Uterine cancer diagnostic testing is extremely important for women to keep themselves in good health conditions. In order to diagnose uterine cancer, a doctor carries out various diagnostic tests considering some of the factors such as stage and type of suspected cancer, age and medical condition of the patient, symptoms and results of prior medical tests if any. The most common types of tests performed by doctors to diagnose a uterine cancer involves: physical examination, imaging tests and surgical biopsy.

Growing awareness among women about uterine ailments coupled with availability of large number of diagnostic tests in market is expected to be the key factor driving the growth of uterine cancer diagnostic testing market. Growing healthcare expenditure and advancement in drug industry are some other factors propelling growth of uterine cancer diagnostic testing market. Performance of uterine cancer diagnostic testing market is primarily determined by increasing incidence rate of uterine diseases across the globe. However, adverse side effects caused by using highly toxic drugs and high cost of treatments are some of the factors restraining the market growth. Also, clinical trials on cancer drugs experience low success rate, which in turn is responsible for sluggish growth in uterine cancer diagnostic testing industry.

Among all test types, hysteroscopy is most commonly recommended uterine cancer diagnostic test. Endometrial biopsy is recommended as confirmatory test for diagnosis of uterine cancer and major part workforce in any histopathology laboratory is occupied with endometrial biopsies.

On the basis of geography, global uterine cancer diagnostic testing market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is projected to hold largest shares in the global market primarily due to growing incidence of uterine cancer among women and innovations in diagnostic techniques. Asia pacific uterine cancer diagnostic testing market is anticipated to witness prominent growth during the forecast period owing to increased healthcare expenditure in developing countries such as India and China.

Some of the key players present in global uterine cancer diagnostic testing market are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Merck & Co., Inc., Becton, Dickinson & Co., Siemens Healthcare Inc., F. Hoffman-La Roche Ltd., GlaxoSmithKline Plc., etc.

Request to Sample Report @  https://www.persistencemarketresearch.com/samples/17005

Ankush Nikam

Ankush Nikam is a seasoned digital marketing professional, having worked for numerous online firms in his distinguished career. He believes in continuous learning, considering that the digital marketing sector’s rapidly evolving nature. Ankush is an avid music listener and loves to travel.